Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The 3 partners collectively have access to the Bracelet data

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Jul 20, 2022 7:32pm

250 Views

Post# 34838820

The 3 partners collectively have access to the Bracelet data

And in the time that the study has been running, Merck KGaA, Pfizer and ONCY would have had opportunity to view the raw data as it came in and seemingly, have been liking what they are seeing.

Enough so that each of the 3 cohorts have now been filled and the study status has moved to "Active- Not Recruiting".

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles